



## The 7<sup>th</sup> NBCNS Research Meeting, November 10 – 11, 2014

### Monday November 10<sup>th</sup>

9.00 – 10.00      *Coffee and registration*

#### **Introduction - Translational Biology and Novel Therapies**

10.00 – 10.10      **Welcome and Challenges**  
Per Kogner, Karolinska Institutet

10.15 – 10.55      ***To be announced***  
Amar Gajjar, St. Jude Children's Research Hospital

11.00 – 11.25      **MTH1 inhibitors in treatment of neuroblastoma**  
Thomas Helleday, Karolinska Institutet

11.30 – 12.30      *Lunch*

#### **Translational Biology and Novel Therapies**

12.30 – 13.10      **Update on the molecular classification of embryonal brain tumors and their underlying genetics**  
Marcel Kool, German Cancer Research

13.15 – 13.25      **The PPM1D encoded WIP1 phosphatase is a novel oncogene and potential therapeutic target in neuroblastoma and medulloblastoma**  
Jelena Milosevic, Karolinska Institutet

13.30 – 13.40      **Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumors**  
Noémie Braekeveldt, Lund University

13.45 – 13.50      *Short break*



## **Novel Therapies**

- 13.50 – 14.15      **Stapled peptides a third class of medicine for hard targets**  
David Lane, Karolinska Institutet
- 14.20 – 14.30      **Inhibition of Rho-associated kinase 2 inhibits malignant progression in neuroblastoma by inducing differentiation and MYCN degradation**  
Cecilia Dyberg, Karolinska Institutet
- 14.35 – 14.45      **Regulation of the nuclear hormone receptor family by MYCN-driven miRNAs affects differentiation and survival in neuroblastoma**  
Diogo Ribeiro, Karolinska Institutet
- 14.50 – 15.20      *Coffee and check-in*

## **Novel Therapies - Into the Clinic**

- 15.20 – 15.30      **Early phase clinical trials are now available to Nordic and Baltic children with cancer**  
Karsten Nysom, Rigshospitalet, University of Copenhagen
- 15.35 – 15.45      **Lithium in the treatment of cognitive late effects after cranial radiotherapy**  
Geraldine Giraud, Karolinska Institutet
- 15.50 – 16.10      **Novel Therapies and How to Translate Preclinical Therapy to Clinical Benefit, discussion**
- 16.10 – 16.15      *Short break*



## Research Strategies

- 16.15 – 16.40      **Drug Discovery: the good the bad and the ugly**  
David Lane, Karolinska Institutet
- 16.45 – 16.55      **The Swedish Biobank for Childhood Tumors**  
Susan Pfeifer, Uppsala University
- 17.00 – 17.05      **Research strategy of Barncancerfonden, request for future interaction?**  
Kerstin Sollerbrant, Barncancerfonden
- 17.05 – 17.20      **How to be more successful, discussion**
- 17.20 – 18.15      **Parallel sessions:**  
  
**Networking/Group discussions: How to be more successful**  
  
**"Meet the expert" session for interested clinicians**  
Amar Gajjar, St. Jude Children's Research Hospital
- 19.00 – 20.30      *Dinner*
- 20.30 – 23.00      **Poster session**



**Tuesday November 11<sup>th</sup>**

**Translational Biology**

- 8.30 – 8.55      **Risk-associated long noncoding RNA *NBAT-1* controls neuroblastoma tumor development and progression via regulating cell proliferation and neuronal differentiation**  
Chandrasekhar Kanduri, University of Gothenburg
- 9.00 – 9.10      **Long non-coding RNA profile in resistance-relapsed neuroblastoma**  
Peter Utnes, The Arctic University of Norway
- 9.15 – 9.25      **SOX9 expressing cells can initiate metastatic relapses in MYCN-driven medulloblastoma**  
Vasil Savov, Uppsala University
- 9.30 – 9.40      **MYCN mediated metabolic plasticity contributes to the pathogenesis in human neuroblastoma**  
Ganna Oliynyk, Karolinska Institutet
- 9.45 – 10.15      *Coffee*

**Translational Biology and Novel Therapies: ALK**

- 10.15 – 10.40      **Anaplastic Lymphoma Kinase function - insights from fly and mouse models**  
Ruth Palmer, University of Gothenburg
- 10.45 – 10.55      **A role for ERK5 in the regulation of MYCN expression by ALK in neuroblastoma**  
Bengt Hallberg, University of Gothenburg
- 11.00 – 11.10      **Emergence of new ALK mutations at relapse of neuroblastoma**  
Tommy Martinsson, University of Gothenburg
- 11.15 – 11.30      Translational Biology, discussion
- 11.30 – 12.30      *Lunch*



## **Translational Biology and Novel Therapies**

- 12.30 – 13.00      **Selected posters** 3 x 7+3 min
- 13.00 – 13.25      ***To be announced***  
Amar Gajjar, St. Jude Children's Research Hospital
- 13.30 – 13.55      **Improving elimination of cancer stem cells**  
Sonia Lain, Karolinska Institutet
- 14.00 – 14.10      **The c-Myc TAD dynamic complex with Pin1 – visible, at last!**  
Maria Sunnerhagen, Linköping University
- 14.15 – 14.25      **Retained capacity to express CHD5 determines ability for terminal neuronal differentiation in neuroblastoma**  
Isabelle Westerlund, Ludwig Institute for Cancer Research  
Karolinska Institutet
- 14.30 – 14.45      **The NBCNS announcement 2015**  
Kerstin Sollerbrant, Barncancerfonden
- Clinical Fellow announcement**  
Per Kogner, Birgitta Lannering, NBCNS
- 14.45 – 15.00      **Discussion and concluding remarks**
- 15.00                *Coffee*